anlotinib + teriprilumab

Anlotinib + teriprilumab is a combination therapy consisting of two investigational agents used in oncology. Anlotinib is a novel oral small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit. It inhibits tumor growth primarily by blocking angiogenesis and cell proliferation pathways[4]. Teriprilumab is a monoclonal antibody immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor on T cells; it enhances anti-tumor immunity by preventing PD-1-mediated inhibition of T-cell activity. The combination has been explored for synergistic effects in various cancers—most notably non-small cell lung cancer (NSCLC)—where it may overcome resistance to prior therapies such as EGFR inhibitors or chemotherapy[1]. Both drugs are developed by Chinese pharmaceutical companies and have shown promising efficacy and manageable toxicity profiles in early clinical reports.